Tag: Food and Drug Administration (FDA)

Viaskin Peanut

Private Law Firm to Investigate Claims on Behalf of Investors in...

It is unknown how this development will affect the ability of the company to eventually offer Viaskin Peanut as an FDA approved therapy.
Viaskin Peanut

FDA Issues Partial Hold on DBV Viaskin Peanut Patch Trial

Another delay for the long-awaited therapy.
Viaskin Patch

DBV Begins Phase 3 Study of Redesigned Viaskin Peanut Patch in...

Viaskin is testing a new version of their patch designed to address the FDA's concerns.
Gut Microbiome

Food Allergies Reversed in Mice by Targeting the Microbiome

Includes media briefing video from the ACS.
EpiPen Shortage

The Netherlands is Experiencing an EpiPen Shortage. Does This Portend a...

There's no need for panic, just vigilance.
Chicken and Egg

Q&A: Egg Allergy

Answers to common questions regarding symptoms, triggers, vaccine safety, and more.
Nestle Acquires Aimmune

Nestlé Acquires Aimmune, Partners with Enterome to Develop Food Allergy and...

Nestlé, the consumer products powerhouse, is expanding its pharmaceutical portfolio with massive investments.
Dupixent (dupilumab)

Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11...

Majority of patients achieved histological disease remission in 16 weeks.
Aquestive AQST-109 Epinephrine Film

Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial

Phase 2 study continues to show AQST-109 is safe and well tolerated.
Viaskin Patch

DBV Announces Positive Topline Results from Phase 3 Trial of Viaskin...

Viaskin Peanut demonstrated a statistically significant treatment effect with 67.0% of subjects meeting the treatment responder criteria after 12 months.